Literature DB >> 25825254

Plasma exchange effectively removes 52- and 60-kDa anti-Ro/SSA and anti-La/SSB antibodies in pregnant women with congenital heart block.

Marta Tonello1, Amelia Ruffatti1, Piero Marson2, Tiziana Tison2, Luca Marozio3, Ariela Hoxha1, Giustina De Silvestro2, Leonardo Punzi1.   

Abstract

BACKGROUND: Pregnant women positive for 52- and 60-kDa anti-Ro/SSA and anti-La/SSB antibodies can suffer from congenital heart block (CHB), a passively acquired autoimmune disease. STUDY DESIGN AND METHODS: We evaluated the efficacy of plasma exchange (PE) in removing 52- and 60-kDa anti-Ro/SSA and anti-La/SSB antibodies in pregnant women with CHB treated with a combined therapy including PE, intravenous immunoglobulins, and steroids. Antibody levels were monitored in 10 consecutive pregnant women diagnosed with CHB and prospectively followed between 2009 and 2013. Assaying was performed using a homemade enzyme-linked immunosorbent assay test on blood samples collected immediately before and after PE sessions.
RESULTS: A significant decrease in mean post-PE antibody levels was noted in all the cases examined. An analysis of antibody level trends in the samples collected before PE sessions showed that there was a steady, significant decrease in 90% of the patients with 52-kDa anti-Ro/SSA, in 80% of those with 60-kDa anti-Ro/SSA antibodies, and in 100% of those with anti-La/SSB antibodies.
CONCLUSION: This study demonstrates that PE is effective in removing antibodies linked to the pathogenesis of CHB. PE treatment was found to have a long-term efficacy in all the women positive for anti-La/SSB antibodies and in most of the women positive for 52- and 60-kDa anti-Ro/SSA antibodies. It is interesting that the significant, immediate, and long-term fall in antibody levels that was observed in these patients took place in all the women whose CHB was reversed. This finding could give PE an important role in the treatment of CHB.
© 2015 AABB.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25825254     DOI: 10.1111/trf.13046

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  7 in total

1.  Low titer, isolated anti Ro/SSA 60 kd antibodies is correlated with positive pregnancy outcomes in women at risk of congenital heart block.

Authors:  Marta Tonello; Ariela Hoxha; Elena Mattia; Alessandra Zambon; Silvia Visentin; Alessia Cerutti; Anna Ghirardello; Ornella Milanesi; Amelia Ruffatti
Journal:  Clin Rheumatol       Date:  2017-02-15       Impact factor: 2.980

2.  Short and long-term outcomes of children with autoimmune congenital heart block treated with a combined maternal-neonatal therapy. A comparison study.

Authors:  Amelia Ruffatti; Alessia Cerutti; Marta Tonello; Maria Favaro; Teresa Del Ross; Antonia Calligaro; Chiara Grava; Margherita Zen; Ariela Hoxha; Giovanni Di Salvo
Journal:  J Perinatol       Date:  2022-06-18       Impact factor: 3.225

3.  Identification of discrete epitopes of Ro52p200 and association with fetal cardiac conduction system manifestations in a rodent model.

Authors:  A Hoxha; A Ruffatti; A Ambrosi; V Ottosson; M Hedlund; L Ottosson; M Anandapadamanaban; M Sunnerhagen; S-E Sonesson; M Wahren-Herlenius
Journal:  Clin Exp Immunol       Date:  2016-09-13       Impact factor: 4.330

4.  First Report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry).

Authors:  Micaela Fredi; Laura Andreoli; Beatrice Bacco; Tiziana Bertero; Alessandra Bortoluzzi; Silvia Breda; Veronica Cappa; Fulvia Ceccarelli; Rolando Cimaz; Salvatore De Vita; Emma Di Poi; Elena Elefante; Franco Franceschini; Maria Gerosa; Marcello Govoni; Ariela Hoxha; Andrea Lojacono; Luca Marozio; Alessandro Mathieu; Pier Luigi Meroni; Antonina Minniti; Marta Mosca; Marina Muscarà; Melissa Padovan; Matteo Piga; Roberta Priori; Véronique Ramoni; Amelia Ruffatti; Chiara Tani; Marta Tonello; Laura Trespidi; Sonia Zatti; Stefano Calza; Angela Tincani; Antonio Brucato
Journal:  Front Cardiovasc Med       Date:  2019-02-28

5.  Treatment and follow-up of fetuses that developed congenital heart block due to autoantibody in two cases.

Authors:  Min Hou; Ying Zhao; Xiao-Wei Liu; Yi-Hua He
Journal:  J Int Med Res       Date:  2020-06       Impact factor: 1.671

6.  Primary Sjogren's syndrome: a great masquerader.

Authors:  Naveen Kumar; Deepanjali Surendran; Bheemanathi Hanuman Srinivas; Chanaveerappa Bammigatti
Journal:  BMJ Case Rep       Date:  2019-12-29

7.  Maternal autoantibody profiles at risk for autoimmune congenital heart block: a prospective study in high-risk patients.

Authors:  Marta Tonello; Amelia Ruffatti; Maria Favaro; Tiziana Tison; Teresa Del Ross; Antonia Calligaro; Ariela Hoxha; Elena Mattia; Leonardo Punzi
Journal:  Lupus Sci Med       Date:  2016-03-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.